MedTrace Logo

Neuroinflammation in COVID-19 and Depression

NCT04854785 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2025-04-22

No results posted yet for this study

Summary

The purpose of this study is to use state of the art brain imaging technology to investigate neuroinflammation in participants with depression after the respiratory symptoms of coronavirus disease 2019 (COVID-19) have passed.

Conditions

  • Major Depressive Episode
  • Covid19

Interventions

OTHER

[18F]FEPPA PET scan

One \[18F\]FEPPA PET for TSPO VT, and one MRI scan

OTHER

[11C]SL25.1188 PET scan

One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Jeffrey H Meyer, M.D., PhD · Brain Health Imaging Centre, Centre for Addiction and Mental Health (CAMH)

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-14
Primary Completion
2023-12-21
Completion
2023-12-21

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04854785 on ClinicalTrials.gov